[Limitation of the therapeutic effort in pediatric intensive care]

V Gonzalo Morales1

  • 1Pediatra, Unidad de Cuidados Intensivos Pediátricos y Programa de Magíster en Bioética, Clínica Alemana-Universidad del Desarrollo y Unidad de Cuidados Intensivos Pediátricos, Hospital Roberto del Río, Universidad de Chile.

Insights

Limiting therapeutic interventions in pediatric intensive care (PICU) involves withholding or withdrawing life support to prevent prolonged suffering. Enhancing bioethics training is crucial for end-of-life decisions in PICU.

Area of Science:

  • Pediatric Intensive Care Medicine
  • Medical Ethics
  • Bioethics

Background:

  • Pediatric intensive care (PICU) has advanced technologically, leading to prolonged dying processes and increased patient/family suffering.
  • The concept of 'limitation of therapeutic effort' addresses treatment adequacy and proportionality to avoid medical futility.
  • English literature uses 'withholding or withdrawal of life-sustaining treatment' instead of 'limitation of treatments'.

Purpose of the Study:

  • To review the current knowledge on limiting therapeutic efforts in pediatric clinical practice.
  • To highlight the ethical challenges in end-of-life care within PICU.
  • To emphasize the need for improved bioethics education for PICU physicians.

Main Methods:

  • Literature review of current knowledge on therapeutic limitation in PICU.
  • Analysis of terminology used in English literature regarding end-of-life care.
  • Examination of the role of bioethics in PICU decision-making.

Main Results:

  • Common methods of limiting treatment include withholding/withdrawing life support and not performing cardiopulmonary resuscitation (CPR).
  • There is a noted deficiency in medical training regarding bioethics among PICU physicians.
  • Decisions regarding end-of-life care are often made without bioethicist consultation.

Conclusions:

  • Limiting therapeutic efforts is a critical aspect of pediatric intensive care, aiming to prevent burdensome treatments.
  • Improved bioethics training and consultation are essential for navigating complex end-of-life decisions in the PICU.
  • Standardizing terminology and practices for limiting life-sustaining treatment is necessary.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
378
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
341
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
484
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
762
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
804
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
647